https://mindmedicinelaw.com/briefing/ai-driven-multimodal-depression-detection-implications-for-psychedelic-trials-20261028-54658The Psychedelic Journalen2026-10-29T15:08:21.397363+00:00AI-Driven Multimodal Depression Detection: Implications for Psychedelic Trialsai depression detection, multimodal diagnostics, psychedelic clinical trials, explainable ai, directional causal fusion, digital health regulation, biometric monitoring, patient selection, mental health technologyhttps://mindmedicinelaw.com/briefing/psilocybin-retreats-connectedness-and-wellbeing-insights-for-public-health-polic-20261028-54657The Psychedelic Journalen2026-10-29T15:07:22.882216+00:00Psilocybin Retreats, Connectedness, and Wellbeing: Insights for Public Health Policypsilocybin retreats, connectedness, mental wellbeing, psychedelic research, public health policy, naturalistic study, integration, regulatory implications, mystical experienceshttps://mindmedicinelaw.com/briefing/genome-analysis-of-gymnopilus-dilepis-illuminates-psilocybin-pathways-20261028-54659The Psychedelic Journalen2026-10-29T15:07:06.122978+00:00Genome Analysis of Gymnopilus dilepis Illuminates Psilocybin Pathwayspsilocybin biosynthesis, gymnopilus dilepis genome, synthetic biology, amino acid metabolism, psychedelic research, clinical supply chain, metabolic engineering, regulatory sciencehttps://mindmedicinelaw.com/briefing/rhelion-s-psilocybin-supply-deal-sweden-s-clinical-trial-signals-market-shift-20261028-54656The Psychedelic Journalen2026-10-28T22:04:41.614328+00:00Rhelion’s Psilocybin Supply Deal: Sweden’s Clinical Trial Signals Market Shiftrhelion, psilocybin supply, sweden clinical trial, european psychedelic research, gmp suppliers, regulatory pathways, clinical trial infrastructure, market dynamics, controlled substances europehttps://mindmedicinelaw.com/briefing/dea-psychedelic-scheduling-challenge-us-research-and-fda-pathways-at-stake-20261028-54652The Psychedelic Journalen2026-10-28T22:04:17.511610+00:00DEA Psychedelic Scheduling Challenge: US Research and FDA Pathways at Stakedea psychedelic scheduling, legal challenge, fda breakthrough therapy, clinical trials, postpartum depression, drug policy, controlled substances, research chill effect, administrative procedure act, us drug regulationhttps://mindmedicinelaw.com/briefing/sweden-launches-psychedelic-clinical-trial-for-social-anxiety-20261028-54537The Psychedelic Journalen2026-10-28T15:06:11.496457+00:00Sweden Launches Psychedelic Clinical Trial for Social Anxietysweden psychedelic trial, social anxiety disorder, filament health, clinical research, scandinavian drug policy, psilocybin studies, industry-academic partnerships, european medicines agency, mental health innovationhttps://mindmedicinelaw.com/briefing/topical-ketamine-for-oral-mucositis-pain-evidence-and-gaps-in-cancer-care-20261027-54706The Psychedelic Journalen2026-10-29T15:07:48.084089+00:00Topical Ketamine for Oral Mucositis Pain: Evidence and Gaps in Cancer Caretopical ketamine, oral mucositis, chemotherapy pain, opioid-sparing, supportive cancer care, randomized controlled trials, adverse events, dosing variability, pediatric oncology, regulatory approvalhttps://mindmedicinelaw.com/briefing/addiction-neuroscience-and-psychedelics-mechanism-based-shifts-in-clinical-conte-20261027-54456The Psychedelic Journalen2026-10-28T15:07:04.057314+00:00Addiction Neuroscience and Psychedelics: Mechanism-Based Shifts in Clinical Contextaddiction neuroscience, psychedelics, mechanism-based treatment, clinical trials, public health policy, reward circuitry, opioid withdrawal, relapse prevention, translational researchhttps://mindmedicinelaw.com/briefing/ketamine-augmented-hypnotherapy-early-clinical-insights-and-research-needs-20261027-54457The Psychedelic Journalen2026-10-28T15:06:28.518024+00:00Ketamine-Augmented Hypnotherapy: Early Clinical Insights and Research Needsketamine-augmented hypnotherapy, kaht, psychedelic-assisted therapy, clinical trials, hypnotherapy, depression, neuroplasticity, patient safety, randomized controlled trialshttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-clinical-evidence-and-challenges-2020-2025-20261027-54441The Psychedelic Journalen2026-10-28T15:05:54.273006+00:00Psychedelic-Assisted Therapy: Clinical Evidence and Challenges (2020–2025)psychedelic-assisted therapy, clinical trials, MDMA, psilocybin, depression, PTSD, protocol heterogeneity, blinding, safety monitoring, ethicshttps://mindmedicinelaw.com/briefing/psychosis-risk-in-psychedelic-therapy-systematic-review-insights-global-1984-202-20261027-54455The Psychedelic Journalen2026-10-28T15:05:36.086901+00:00Psychosis Risk in Psychedelic Therapy: Systematic Review Insights (Global, 1984–2025)psychedelics, psychosis risk, systematic review, clinical trials, screening protocols, policy implications, public health, psychiatric safety, regulation, emergency datahttps://mindmedicinelaw.com/briefing/feasibility-of-psychedelic-like-vr-for-ocd-multicentre-study-in-germany-and-ital-20261026-54698The Psychedelic Journalen2026-10-29T15:08:03.573790+00:00Feasibility of Psychedelic-Like VR for OCD: Multicentre Study in Germany and Italyvirtual reality, psychedelic therapy, obsessive-compulsive disorder, digital therapeutics, clinical trials, psychological flexibility, non-pharmacological interventions, regulatory implications, cybersickness, ego dissolutionhttps://mindmedicinelaw.com/briefing/neuroplasticity-as-a-therapeutic-target-in-depression-implications-for-psychedel-20261026-54458The Psychedelic Journalen2026-10-28T15:08:08.992042+00:00Neuroplasticity as a Therapeutic Target in Depression: Implications for Psychedelic Researchneuroplasticity, major depressive disorder, bdnf-trkb pathway, mtorc1 signaling, psychedelic research, clinical trial design, synaptogenesis, biomarkers, regulatory sciencehttps://mindmedicinelaw.com/briefing/striatal-plasticity-and-relapse-risk-in-anorexia-nervosa-implications-for-neurom-20261026-54470The Psychedelic Journalen2026-10-28T15:07:54.185945+00:00Striatal Plasticity and Relapse Risk in Anorexia Nervosa: Implications for Neuromodulatory Researchstriatal plasticity, anorexia nervosa relapse, putamen gradient, biomarkers, psychedelic-assisted therapy, neuromodulation, reward processing, clinical trials, brain imaging, habitual behaviorhttps://mindmedicinelaw.com/briefing/chemsex-emergencies-clinical-and-policy-challenges-for-ems-in-europe-20261026-54442The Psychedelic Journalen2026-10-28T15:07:36.915196+00:00Chemsex Emergencies: Clinical and Policy Challenges for EMS in Europechemsex, emergency medical services, public health, syndromic approach, polysubstance use, harm reduction, protocol development, operational risk, european policyhttps://mindmedicinelaw.com/briefing/whole-brain-modeling-and-subtype-specific-regulation-in-adolescent-mdd-20261026-54471The Psychedelic Journalen2026-10-28T15:07:19.583490+00:00Whole Brain Modeling and Subtype-Specific Regulation in Adolescent MDDadolescent depression, major depressive disorder, whole brain modeling, computational psychiatry, personalized neuromodulation, psychedelic clinical trials, neuroimaging biomarkers, subtype-specific interventionshttps://mindmedicinelaw.com/briefing/sex-differences-in-psilocybin-vs-escitalopram-for-mdd-bayesian-reanalysis-20261026-54421The Psychedelic Journalen2026-10-28T15:06:45.816607+00:00Sex Differences in Psilocybin vs. Escitalopram for MDD: Bayesian Reanalysispsilocybin, escitalopram, major depressive disorder, sex differences, bayesian analysis, psychedelic trials, clinical trial design, anxiety outcomes, sexual dysfunction, personalized psychiatryhttps://mindmedicinelaw.com/briefing/trump-administration-advances-psychedelic-therapy-for-veterans-20261025-54654The Psychedelic Journalen2026-10-28T22:04:29.499037+00:00Trump Administration Advances Psychedelic Therapy for Veteransveterans, psychedelic therapy, trump administration, department of veterans affairs, mdma, psilocybin, policy, public health, clinical trials, federal regulationhttps://mindmedicinelaw.com/briefing/control-conditions-in-ivr-trials-implications-for-psychedelic-research-20261023-54699The Psychedelic Journalen2026-10-29T15:09:19.030385+00:00Control Conditions in IVR Trials: Implications for Psychedelic Researchivr control conditions, virtual placebo, psychedelic research, clinical trial design, digital therapeutics, randomized controlled trials, methodological rigor, fda guidance, mental health interventionshttps://mindmedicinelaw.com/briefing/bias-aware-meta-analysis-method-advances-psychedelic-research-synthesis-20261023-54700The Psychedelic Journalen2026-10-29T15:08:58.186175+00:00Bias-Aware Meta-Analysis Method Advances Psychedelic Research Synthesisbias-aware meta-analysis, psychedelic research, evidence synthesis, heterogeneous studies, clinical trials, regulatory policy, reproducibility, statistical methods, fixed-effect model, random-effects modelhttps://mindmedicinelaw.com/briefing/mri-guided-reverse-translational-framework-in-psychiatry-research-20261023-54714The Psychedelic Journalen2026-10-29T15:08:37.700319+00:00MRI-Guided Reverse-Translational Framework in Psychiatry Researchmri volumetric analysis, reverse translation, psychiatric research, animal models, psychedelic mechanisms, clinical trial design, brain structure, translational neurosciencehttps://mindmedicinelaw.com/briefing/suicidality-during-intranasal-es-ketamine-analysis-of-2026-retrospective-cohort--20261021-54484The Psychedelic Journalen2026-10-28T22:04:58.744894+00:00Suicidality During Intranasal (Es)ketamine: Analysis of 2026 Retrospective Cohort Dataintranasal esketamine, suicidality, retrospective cohort study, ketamine safety, treatment-resistant depression, real-world evidence, FDA REMS, psychiatric protocols, post-marketing surveillance